New technology enhances breast cancer surgery precision in international trial at Mid and South Essex hospitals
One of the participants was a Corringham nurse
Last updated 22nd May 2026
A large clinical trial has demonstrated that innovative technology is enabling surgeons to remove breast cancer tumours with greater precision.
The trial, which spanned several countries, included 418 patients.
Among the 19 UK participants was Heidi Jones from Corringham, Essex, a nurse at Basildon Hospital who works with breast cancer patients.
Diagnosed with breast cancer in 2025, Heidi opted to join the study.
She said the new procedure was less uncomfortable compared to traditional methods and provided her peace of mind.
Reflecting on her decision to participate, Heidi shared, “Having this procedure was far less uncomfortable for me than for other women I know who have experienced traditional methods, which gave me real peace of mind and made it a far less daunting experience."
Her motivation stemmed from the desire to increase her chances of being cancer-free and spend time with her granddaughter.
Mid and South Essex NHS Foundation Trust was one of two UK centres participating in the trial, joined by others from the US, Canada, and Austria.
The Trust evaluated the Breast Cancer Locator (BCL) System, comparing it to conventional methods for lumpectomy surgery, which involves removing portion of breast tissue.
Results indicated that the BCL System significantly improved the ability to remove the complete tumour, reducing the positive margin rate by 32% and decreasing the need for second surgeries by 34%.
Mr Wayne Chicken, Heidi’s breast surgeon, explained how the BCL technology provides precise information on tumour size, shape, and location.
“The BCL technology meant we were able to define the precise location and boundaries of even the most difficult tumours, and to view tumours in 3D before and during surgery,” he said.
Heidi’s surgery was successful, removing the tumour completely, and she has been cancer-free since her operation in July last year.
Heidi expressed her gratitude towards the staff and the technology that facilitated her journey.
She said, “I’m forever grateful to everyone involved in this study at the Trust, as well as those who created the technology in the US.”
Heidi is hopeful her participation will contribute to improving future cancer care for others.